WEST CHESTER, PA / ACCESSWIRE / February 16, 2021 / Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the pricing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.00 per share, for gross … Add to … Get the latest EPS stock quote information from Zacks Investment Research. Virpax Pharmaceuticals Inc. SEC filings breakout by MarketWatch. Virpax Pharmaceuticals is a company that develops products for pain management. Virpax Pharmaceuticals Inc. Virpax Pharmaceuticals, Inc. operates as a biotech company. Virpax Pharmaceuticals Description. View the VRPX U.S. Securities and Exchange Commission reporting information. The total size of the offering was $18,000,000 based on an initial share price of $10.00. Virpax Pharmaceuticals is committed to developing products that manage pain and all its complexities, while minimizing risks to patients and society. Prior to founding Virpax in 2016, Mr. Mack founded Scilex Pharmaceuticals and served as President and CEO until February 2018. Scilex was sold to a publicly traded company. Mr. Mack founded his first pharmaceutical company, ProSolus Pharmaceuticals, in 2009 where he served as President before selling the company to Mission Pharmacal in 2015. Mr. VRPX: Virpax Pharmaceuticals, Inc. - Insider Transactions Get the latest Insider Transactions for Virpax Pharmaceuticals, Inc. from Zacks Investment Research Virpax Pharmaceuticals, Inc. CIK: 1708331. All quotes delayed a minimum of 15 minutes. Registration Statement. A brief financial summary of Virpax Pharmaceuticals Inc as well as the most significant critical numbers from each of its financial reports. The Company specializes in developing novel drug delivery systems across various pain indications. With Virpax Pharmaceuticals stock trading at $6.45 per share, the total value of Virpax Pharmaceuticals stock (market capitalization) is $29.08M. Virpax Pharmaceuticals Inc. Before founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in … (1) Covers 1,009,505 shares of common stock issuable under the Virpax Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). Download PDF Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Virpax Pharmaceuticals Inc. Virpax Pharmaceuticals, Inc. operates as a biotech company. Get the latest Price and Consensus Chart for Virpax Pharmaceuticals, Inc. from Zacks Investment Research View VRPX: Virpax Pharmaceuticals, Inc.investment & stock information. Its products include DSF100, Probudur, Epoladerm and NES100. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for … Show section Company profile for Virpax Pharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Industry: Pharmaceuticals: Major. Highlights. Virpax Pharmaceuticals had issued 1,800,000 shares in its initial public offering on February 17th. The total size of the offering was $18,000,000 based on an initial share price of $10.00. After the expiration of Virpax Pharmaceuticals' lock-up period, major shareholders and company insiders will be able to sell their shares of the company. Summary Financials People Technology Signals & News. DGAP-News: Virpax(R) Pharmaceuticals Inc. / Key word(s): IPO17.02.2021 / 05:47 The issuer is solely responsible for the content of this announcement.Virpax(R) Pharmaceuticals Announces Pricing of Initial Public OfferingWEST CHESTER, PA, February 16, 2021 - Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical … Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments. On April 7, 2021, Virpax Pharmaceuticals, Inc. (the "Company") entered into an employment agreement with Christopher Chipman, the Company's Chief Financial Officer (the "Chipman Employment Agreement"). Get a brief overview of VIRPAX PHARMA INC financials with all the important numbers. Virpax Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data. SEC Filings provided by EDGAR Online, Inc. Prev Page Next Page. Virpax Pharmaceuticals, Inc. Common Stock (VRPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Virpax Pharmaceuticals (VRPX) stock price, charts, trades & the US's most popular discussion forums. Operating income can be defined as income after operating expenses have been deducted and … Monthly Visits 4,354. Corporate Governance Virpax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. Virpax Pharmaceuticals net profit margin from 2020 to 2021. Scilex was sold to a publicly traded company. Anthony P Mack is Chairman/CEO at Virpax Pharmaceuticals Inc. See Anthony P Mack's compensation, career history, education, & memberships. Selected key stats of Virpax Pharmaceuticals, Inc. (VRPX) including 10 year stock price and latest news. View the VRPX U.S. Securities and Exchange Commission reporting information. Anthony Mack, Chairman and CEO of Virpax, will … Access detailed quarterly and annual financial reports for Virpax Pharmaceuticals Inc. View the balance sheet, income statement, cash flow and more. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more. June 2, 2020 Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Christopher M. Chipman, CPA, Chief Financial … Virpax Pharmaceuticals net income from 2020 to 2021. These include IPhone / Mobile Compatible, Viewport Meta, and SPF. -0.09 (-2.00%) DATA AS OF Apr 16, 2021 1:10 PM ET. The company is focused on developing pharmaceutical product candidates for pain management. Headline. VRPX: Virpax Pharmaceuticals, Inc. industry comparisons. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. The Income Statement (earnings report) for Virpax Pharmaceuticals Inc. Find the company's financial performance, revenue, and more. BERWYN, Pa.-- (BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other rec... 1 month ago - Business Wire Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts Apr 22, 2021 Virpax Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) has raised a total of $20.4M in funding over 3 rounds. Net profit margin can be defined as net Income as a portion of total sales revenue. BERWYN, Pa.-- (BUSINESS WIRE)-- #pharma -- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. View the basic VRPX option chain and compare options of Virpax Pharmaceuticals, Inc. on Yahoo Finance. BERWYN, Pa.--(BUSINESS WIRE)-- Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments.“We successfully completed our initial public offering (IPO) of 1,800,000 shares of our common stock in mid-February and immediately began our IND enabling … In addition, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers an indeterminate amount of interests to be offered or sold pursuant to the employee benefit … Rating as of Jun 16, 2021. Their latest funding was raised on Feb 16, 2021 from a Series C round. Its products include DSF100, Probudur, Epoladerm and NES100. Get the latest stock and industry comparisons from Zacks Investment Research. Anthony Mack, Chairman and CEO of Virpax, will be giving … WEST CHESTER, PA / ACCESSWIRE / February 19, 2021 / Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $18.0 … Get the latest Greek Montage stock quote information from Zacks Investment Research It offers a transdermal metered-dose spray, an aerosol-based system that delivers active pharmaceutical ingredients (API) as a patch-in-a-can, and liposomal in hydrogel encapsulation that provides prolonged postoperative analgesia. $4.41. Sample 10-K Year-over-Year (YoY) Comparison. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for. Employee Profiles. Nasdaq 100. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) Connect to CRM . After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. finance.yahoo.com - June 2 at 12:36 PM. Its products include metered-dose spray, liposomal gel … Monthly Visits Growth -6.93%. S-1. It is focused on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Annual stock financials by MarketWatch. Free forex prices, toplists, indices and lots more. Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Virpax Pharmaceuticals (VRPX) stock price, charts, trades & the US's most popular discussion forums. Our proprietary delivery systems will reinvent how patients and prescribers manage pain worldwide. Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. It is focused on pain management by developing and delivering non-opioid and non-addictive pharmaceutical … Virpax Pharmaceuticals stock was originally listed at a price of $6.53 in Feb 17, 2021. VIRPAX PHARMACEUTICALS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for VIRPAX PHARMACEUTICALS, INC. Stock | VRPX | US9282511073 VRPX: Virpax Pharmaceuticals, Inc. Greek Montage stock information. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in 10/09/2020. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray. Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) is actively using 26 technologies for its website, according to BuiltWith.